carboplatin,durvalumab,edit-301,paclitaxel,olaparib,pembrolizumab,bevacizumab
editas medicine, inc.,astrazeneca,merck,roche
['gynca', 'duo-o', 'gyn', 'ruby', 'kn-826']
exciting times for #immunotherapy in #gynca, reflected by the encouraging data from kn-826, ruby, and duo-o trials presented at #asco23. considering each one of the females represented by these provocative survival curves! 
MD, MSc, Medical Oncologist, Oncology Unit, 3rd Dpt of Internal Medicine, @uoaofficial Sotiria Hospital